Upcoming Meeting

2021 IBCN Update Series
September 25, October 30, and December 4

1600-1730 CET 

 

Dear Friends & Colleagues,

 

We are going to have to cancel our virtual and in-person IBCN meeting this year. Instead we are excited the IBCN Update Series on  September 25, October 30, and December 4th from 1600-1730 CET. 

Please mark your calendars and we will forward more details about the series and links closer to that date. We are still considering an in-person meeting in Montreal for 2022.

Please remember: The IBCN Update Series is only open to members. If you have not registered yourself as a member and paid your dues (possible now by PayPal on IBCN webpage), please contact us.

IBCN Update Series

September 25 1600-1730 CET

IBCN Update on ctDNA

Moderator: Tilman Todenhöfer

1600 ctDNA: Molecular residual disease and treatment response measurements

  • Lars Dyrskjøt

 

1615 ctDNA: Insights into biology of urothelial carcinoma

  • Alex Wyatt

 

1630 ctDNA in the clinic and clinical trials

  • Matt Galsky

 

1645 Panel discussion with Q&A

 

October 30 IBCN 1600-1730 CET

Update on Bladder Preservation after Neoadjuvant Therapy

Moderator: Ashish Kamat

 

1600 Clinical staging after NAC

  • Roland Seiler

 

1610 Abstract presentation-“Experience with bladder sparing after clinical complete response to neoadjuvant chemotherapy”

  • Harry Herr

 

1615 Biology of DNA Damage Repair Gene Alterations

  • Kent Mouw

 

1630 Marker driven bladder preservation – clinical trial update

  • Gopa Iyer

 

1645 Panel discussion with Q&A

 

December 4th 1600-1730 CET

IBCN Update on Biology of BCG Response

Moderator: Lars Dyrskjøt

 

1600 BCG immunology and sexual dimorphism in bladder immunity

  • Molly Ingersoll

 

1615 Somatic features of response to BCG

  • David Müller

 

1625 Transcriptomic correlates to BCG response

  • Tahlita Zuiverloon

 

1635 Multi-omics correlates to BCG response

  • Trine Strandgaard

 

1645 Immunophenotyping of BCG response and resistance

  • Amir Horowitz

 

1700 Clinical trial update

  • Josh Meeks

 

1705 Panel discussion with Q&A

Looking forward to seeing you again,